相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Intracellular NAD+ depletion induces autophagic death in multiple myeloma cells
Michele Cea et al.
AUTOPHAGY (2013)
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition
Michele Cea et al.
BLOOD (2012)
The NAD metabolome - a key determinant of cancer cell biology
Alberto Chiarugi et al.
NATURE REVIEWS CANCER (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Reciprocal Potentiation of the Antitumoral Activities of FK866, an Inhibitor of Nicotinamide Phosphoribosyltransferase, and Etoposide or Cisplatin in Neuroblastoma Cells
Cristina Travelli et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (< 12 months)
Christopher P. Venner et al.
LEUKEMIA & LYMPHOMA (2011)
Compromising the Unfolded Protein Response Induces Autophagy-Mediated Cell Death in Multiple Myeloma Cells
Anne-Sophie Michallet et al.
PLOS ONE (2011)
Regulation of cancer cell metabolism
Rob A. Cairns et al.
NATURE REVIEWS CANCER (2011)
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes
Ebenezer David et al.
BLOOD (2010)
The Secret Life of NAD+: An Old Metabolite Controlling New Metabolic Signaling Pathways
Riekelt H. Houtkooper et al.
ENDOCRINE REVIEWS (2010)
Potent synergistic interaction between the Nampt inhibitor AP0866 and the apoptosis activator TRAIL in human leukemia cells
Gabriele Zoppoli et al.
EXPERIMENTAL HEMATOLOGY (2010)
The NF-KB Inhibitor LC-1 Has Single Agent Activity in Multiple Myeloma Cells and Synergizes with Bortezomib
Elisabeth J. Walsby et al.
MOLECULAR CANCER THERAPEUTICS (2010)
APO866 activity in hematologic malignancies: a preclinical in vitro study
Michele Cea et al.
BLOOD (2009)
The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies
Aimable Nahimana et al.
BLOOD (2009)
The Small Molecule GMX1778 Is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors
Mark Watson et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE
Santina Bruzzone et al.
PLOS ONE (2009)
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Matthew G. Vander Heiden et al.
SCIENCE (2009)
NAD depletion by FK866 induces autophagy
Richard A. Billington et al.
AUTOPHAGY (2008)
Bortezomib-resistant nuclear Factor-κB activity in multiple myeloma cells
Stephanie Markovina et al.
MOLECULAR CANCER RESEARCH (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor
Kyle Holen et al.
INVESTIGATIONAL NEW DRUGS (2008)
Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival
Hongying Yang et al.
CELL (2007)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
George Mulligan et al.
BLOOD (2007)
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells
AM Roccaro et al.
CANCER RESEARCH (2006)
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma
S Lonial et al.
BLOOD (2005)
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
D Chauhan et al.
CANCER CELL (2005)
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
T Hideshima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy
M Muruganandham et al.
CLINICAL CANCER RESEARCH (2005)
The new life of a centenarian:: signalling functions of NAD(P)
F Berger et al.
TRENDS IN BIOCHEMICAL SCIENCES (2004)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
K Podar et al.
BLOOD (2001)
分享论文
